Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavin J Kilpatrick

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|August 6, 2021
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic AgentGavin J Kilpatrick
Medicinal Research Reviews|June 14, 2005
Morphine-6-glucuronide: actions and mechanismsGavin J Kilpatrick, Terry W Smith
Current Opinion in Anaesthesiology|July 11, 2006
Drug development in anaesthesia: industrial perspectiveGavin J Kilpatrick, Gary S Tilbrook
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Memantine. MerzGavin J Kilpatrick, Gary S Tilbrook
Anesthesia and Analgesia|January 19, 2012
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulationHugh R Wiltshire, Gavin J Kilpatrick, Gary S Tilbrook, et al.
Anesthesia and Analgesia|December 23, 2011
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokineticsLaurie J Antonik, D Ronald Goldwater, Gavin J Kilpatrick, et al.
Anesthesiology|June 23, 2007
CNS 7056: a novel ultra-short-acting BenzodiazepineGavin J Kilpatrick, Margaret S McIntyre, Richard F Cox, et al.
Frontiers in Immunology|January 1, 2021
Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune SignaturesJacob D Galson, Sebastian Schaetzle, Rachael J M Bashford-Rogers, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|August 6, 2021
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic AgentGavin J Kilpatrick
Medicinal Research Reviews|June 14, 2005
Morphine-6-glucuronide: actions and mechanismsGavin J Kilpatrick, Terry W Smith
Current Opinion in Anaesthesiology|July 11, 2006
Drug development in anaesthesia: industrial perspectiveGavin J Kilpatrick, Gary S Tilbrook
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Memantine. MerzGavin J Kilpatrick, Gary S Tilbrook
Anesthesia and Analgesia|January 19, 2012
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulationHugh R Wiltshire, Gavin J Kilpatrick, Gary S Tilbrook, et al.
Anesthesia and Analgesia|December 23, 2011
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokineticsLaurie J Antonik, D Ronald Goldwater, Gavin J Kilpatrick, et al.
Anesthesiology|June 23, 2007
CNS 7056: a novel ultra-short-acting BenzodiazepineGavin J Kilpatrick, Margaret S McIntyre, Richard F Cox, et al.
Frontiers in Immunology|January 1, 2021
Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune SignaturesJacob D Galson, Sebastian Schaetzle, Rachael J M Bashford-Rogers, et al.
Pageof 1